Cargando…
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies
Objectives: Clinical benefits of immune-checkpoint blockade (ICB) versus standard chemotherapy have been established in unselected non-small cell lung cancer (NSCLC). However, the response to ICB therapy among patients is heterogeneous in clinical practice. Materials and Methods: We retrospectively...
Autores principales: | Ma, Si-Cong, Tang, Xin-Ran, Long, Li-Li, Bai, Xue, Zhou, Jian-Guo, Duan, Zhi-Jiao, Wang, Jian, Fu, Qiang John, Zhu, Hong-Bo, Guo, Xue-Jun, Zhang, Yan-Pei, Guo, Ze-Qin, Wu, De-Hua, Dong, Zhong-Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078693/ https://www.ncbi.nlm.nih.gov/pubmed/33996262 http://dx.doi.org/10.1080/2162402X.2021.1909296 |
Ejemplares similares
-
Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice
por: Ma, Si-Cong, et al.
Publicado: (2022) -
De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021) -
Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation
por: Guo, Xue-Jun, et al.
Publicado: (2023) -
Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage
por: Su, Shan, et al.
Publicado: (2021) -
Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Schubert, Philipp, et al.
Publicado: (2020)